Mineralys Therapeutics (MLYS) – Analysts’ Recent Ratings Updates

Several analysts have recently updated their ratings and price targets for Mineralys Therapeutics (NASDAQ: MLYS):

• 3/15/2026 – Mineralys Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 3/13/2026 – Mineralys Therapeutics had its “hold” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $30.00 price target on the stock.
• 3/13/2026 – Mineralys Therapeutics had its price target raised by Bank of America Corporation from $46.00 to $51.00. They now have a “buy” rating on the stock.
• 3/10/2026 – Mineralys Therapeutics was given a new $56.00 price target by HC Wainwright. They now have a “buy” rating on the stock.
• 3/7/2026 – Mineralys Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 1/22/2026 – Mineralys Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insider Buying and Selling at Mineralys Therapeutics

In other Mineralys Therapeutics news, insider David Malcom Rodman sold 14,058 shares of the business’s stock in a transaction dated Friday, March 13th. The stock was sold at an average price of $26.26, for a total transaction of $369,163.08. Following the transaction, the insider owned 76,140 shares in the company, valued at $1,999,436.40. The trade was a 15.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Jon Congleton sold 16,236 shares of the company’s stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $32.62, for a total value of $529,618.32. Following the completion of the sale, the chief executive officer directly owned 639,151 shares of the company’s stock, valued at $20,849,105.62. The trade was a 2.48% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 363,325 shares of company stock valued at $12,298,347. 33.24% of the stock is owned by insiders.

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.